267 research outputs found
Ten-Years of Experience with Weekly Chemotherapy in Metastatic Breast Cancer Patients: Multivariate Analysis of Prognostic Factors.
No full textWe conducted a phase II study to determine the activity and tolerability of weekly paclitaxel, 5-fluorouracil (5-FU) and folinic acid plus granulocyte colony-stimulating factor (G-CSF) support in anthracycline-pre-treated or -resistant metastatic breast cancer patients. The phase II study was designed following the Simon optimal-two stage method. Patients received paclitaxel 80 mg/m, folinic acid 10 mg/m and bolus infusion of 5-FU 300 mg/m every week plus G-CSF on day 3 for 24 consecutive weeks in the absence of disease progression. From May 1998 to May 2000, 51 patients entered the study. Patients received a median relative dose intensity of 97.5% (range 81-100%). No severe toxicities were observed. Seven patients (14%) experienced neutropenia grade 2. Seven patients (14%) experienced grade 2 anemia. Two patients (4%) experienced severe asthenia. Three out of 50 evaluable patients [6%, 95% confidence interval (CI) 2-12.6%] showed a complete response, whereas 23 (46%, 95% CI 32.2-59.8%) had a partial response, with an overall response rate of 52% (95% CI 38.2-65.8%). In addition, eight patients (15.7%) had stable disease. In the 13 patients untreated for metastatic disease, the overall response rate was 92.3% (CI 77.8-100), with one complete response and 11 partial responses (84.6% CI 65-100%). In the whole group, the median time to progression and overall survival were 8 (range 1-18) and 14 months (95% CI 11-17), respectively. Thus, in metastatic breast cancer patients pre-treated with anthracyclines, the weekly administration of paclitaxel, 5-FU and folinic acid with G-CSF support seems to be extremely tolerable and active
Antigeni associati a tumori definiti da anticorpi monoclonali nel carcinoma della mammella
No full textUse of monoclonal antibodies to human breast tumor associated antigens in fine needle aspirate cytology
No full textProspective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
Get PDFAlessandra Fabi,1 Diana Giannarelli,2 Paola Malaguti,1 Gianluigi Ferretti,1 Sabrina Vari,1 Paola Papaldo,1 Cecilia Nisticò,1 Mauro Caterino,3 Roy De Vita,4 Marcella Mottolese,5 Laura Iacorossi,6 Francesco Cognetti1 1Department of Medical Oncology, 2Biostatistic Unit, 3Service of Radiology, 4Operative Unit of Plastic and Reconstructive Surgery, Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy; 5Department of Pathology, 6Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined schedules, but the need for synthetic solvents contributes to the severe toxicities and may have a negative impact on the efficacy. Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is a colloidal suspension of paclitaxel and human serum albumin initially developed to avoid the toxicities associated with conventional taxanes.Patients and methods: The aim of this prospective, single-center open-label, noncomparative study was to evaluate the efficacy and safety of nab-paclitaxel in MBC patients pretreated with taxanes. The patients were treated with nab-paclitaxel as a single agent, 260 mg/m2 on day 1 of each 3-week cycle or 125 mg/m2 weekly. The primary endpoint was the overall response rate (ORR). Secondary objectives were duration of response, clinical benefit rate, progression-free survival (PFS), overall survival, and safety.Results: A total of 42 patients (median age 48 years, median Eastern Cooperative Oncology Group performance status 0, triple-negative MBC 19%, all pretreated with a taxane-based therapy, mainly in advanced disease) were enrolled in the study. The ORR was 23.8%, including one complete response (2.4%) and nine partial responses (21.4%); the disease control rate was 50%. The median duration of response was 7.2 months. After a median follow-up of 9 months, the median PFS was 4.6 months. ORR and PFS were similar irrespective of the previous chemotherapy lines, metastatic sites, and biomolecular expression. Nab-paclitaxel was well tolerated, and the most frequent treatment-related toxicities were mild to moderate (grades 1–2).Conclusion: This real-life study shows that nab-paclitaxel has a significant antitumor activity and a manageable safety profile in patients pretreated with taxanes and experiencing a treatment failure after at least one line of chemotherapy. Keywords: nab-paclitaxel, metastatic breast cancer, anthracycline
Brachial plexus neuropathy as unusual onset of diffuse neurolymphomatosis
Get PDF: We present a patient with a large B cell gastric lymphoma in total remission who, after 4 months, developed a fatal progressive peripheral neuropathy with an unusual early involvement of the right brachial plexus. No evidence of lymphoma was found at whole body computed tomography, magnetic resonance imaging of the head, cervical spine and right brachial plexus, bone marrow biopsy or repeated lumbar punctures. The diagnosis of neurolymphomatosis was made only at postmortem examination
Transformation and tumor progression are frequently associated with the expression of the alpha 3 beta 1 heterodimer in solid tumors.
No full text2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts)
No full textSession title: Gastrointestinal Malignancies - Colorectal Cancer Session type: Poster Session Track: Gastrointestinal Malignancies
Abstract number: 2196
Background: Experimental and clinical evidence supports a role for the circadian timing system in cancer. Gender and delivery schedule (chronomodulated or conventional) influence overall survival (OS) in mCRC pts (Giacchetti 2014). Circadian rhythms are generated by a transcription-translation–based oscillatory loop and involve a set of clock genes including PERIOD, CLOCK, BMAL1, CRY. Here we evaluated the expression of CLOCK gene-related miRNAs and SNPs in mCRC pts and their effect according to gender.
Material and Methods: We studied 83 first line mCRC pts treated with chemotherapy plus cetuximab. Specific CLOCK polymorphisms (SNPs) (rs11133373C/G, rs11133391T/C, rs1801260T/C) and miRNAs expression level (miR-192–206–132–194–219) were performed on formalin fixed paraffin embedded tissues in 77 pts. OS was the primary study endpoint.
Results: Median age 59y (30–85); male/female (M/F) 50/33; median follow-up 25 m (1–132); median PFS was 14 m (95%CI 10–19) and median OS was 35 m (95%CI 22–47). PFS and OS were significantly better in F: PFS M/F = 12/19 m (95%CI 8–16/11–27) p=0.03; OS M/F = 31/50 m (95%CI 22–39/35–64) p=0.03. Increased OS in F vs M was related to high expression level (H) of miR206 (p=0.003), miR219 (p=0.003) and miR194 (p=0.02), and low expression (L) of miR132 (p=0.06). OS was also better in F vs M in the presence of genotype RS11133373C/C (p=0.01), RS1801260T/T (p=0.07) and RS11133391T/T (p=0.06). Subgroup analysis in females showed that OS was significantly better when ≥2 beneficial miRNA were simultaneously expressed vs 0/1 (58 m vs 15 m, p=0.0002) and this effect was additionally increased by the presence of RS11133391T/T polymorphism (median OS 87 m). Although no difference in OS was observed between M and F respect to L of miR206 and H of miR132, OS was significantly decreased in F when L of miR206 and H of miR132 were simultaneously expressed vs 0/1 (11 m vs 56 m, p=0.02). No difference in OS was observed in subgroup analysis in males.
Conclusions: A set of SNPs and miRNAs related to CLOCK gene, principal regulator of the molecular clock, identifies a subgroup of pts who benefits of a gender related difference in survival in mCRC. Supported by AIRC11770
No conflict of interest
Immunohistochemical expression of biomarkers in patients with highly chemorefractory colorectal liver metastases (mCRC) pre- and post-radioembolization (RE) with yttrium-90 resin microspheres
No full textc-Myc deregulation is involved in melphalan resistance of Multiple Myeloma: role of PDGF-BB
No full textCardiomyopathies in children: Classification, diagnosis and treatment
No full textPurpose of review Cardiomyopathies are rare in the pediatric population, but significantly impact on morbidity and mortality. The present review aims to provide an overview of cardiomyopathies in children and some practical guidelines for their prognostic stratification and management. Recent findings Pediatric cardiomyopathies may present as isolated cardiac muscle disease or in the context of complex clinical syndromes. The etiologic characterization represents an important step in the diagnosis and treatment of cardiomyopathies because of its impact on prognosis and on therapeutic measures. Indeed, replacement therapy is nowadays widely available and changes the natural history of the disease. More complex is the management of isolated cardiomyopathies, which lack specific therapies, mainly aimed at symptomatic relief. In this context, heart transplantation shows excellent outcomes in children, but wait-list mortality is still very high. Device therapy for sudden cardiac death prevention and the use of mechanical assist devices are becoming more common in the clinical practice and may help to reduce mortality. Summary Providing insight into pediatric cardiomyopathies classification helps in the prognostication and management of such diseases. Recent years witnessed a significant improvement in mortality, but future research is still needed to improve quality of life and life expectations in the pediatric population
- …
